Primjeri korištenja Enzyme replacement na Engleski i njihovi prijevodi na Hrvatskom
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Treatment should be approached with caution in patients who have exhibited symptoms of hypersensitivity to velaglucerase alfa or other enzyme replacement therapy.
Therefore no conclusions on the effect of enzyme replacement therapy on the neurological manifestations of the disease can be drawn.
Talk to your doctor before taking Galafold if you are currently taking enzyme replacement therapy.
may limit the renal response to enzyme replacement therapy.
Some patients have had to resume long-term enzyme replacement therapy and/or receive a stem cell transplant see section 5.1.
Enzyme replacement therapy for Gaucher disease type I with clinically significant manifestations(anemia, thrombocytopenia, scarp- and splenomegaly,
eventually it will work for enzyme replacement therapies.
Replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease α-galactosidase A deficiency.
The most important serious side effects seen with other pancreatic enzyme replacement medicines are‘anaphylactic shock' and fibrosing colonopathy.
The rationale for enzyme replacement therapy is to restore a level of enzymatic activity sufficient to hydrolyze the accumulated substrate
My theory works for Pompe, and eventually it will work for enzyme replacement therapies.
And eventually it will work for enzyme replacement therapies My theory works for Pompe, for other lysosomal storage disorders.
Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis I(MPS I;
Cerezyme(imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic(Type 1)
this could be an advantage compared with other authorised treatments such as enzyme replacement which are given by infusion(drip) into a vein.
is used as enzyme replacement therapy in Fabry disease, where the level of-galactosidase enzyme activity is absent or lower than normal.
For patients with stable disease who switch from enzyme replacement therapy to eliglustat, monitoring for disease progression(e.g. after 6 months with regular monitoring thereafter)
Laronidase is used as‘enzyme replacement therapy', which means that it replaces the enzyme that is missing in patients with MPS I. This controls the symptoms of MPS I,
10-15 years in females, therefore enzyme replacement therapy should be introduced in patients of any age
to evaluate the effectiveness of enzyme replacement therapy, ultimately leading to improvement in the safe